Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration

British Journal of Ophthalmology

Volumn 100, Issue 12, 2016, Pages 1640-1645

  Barthelmes, Daniel ^a,b   Campain, Anna ^a   Nguyen, Phuc ^a   Arnold, Jennifer J ^c   McAllister, Ian L ^d   Simpson, Judy M ^e   Hunyor, Alex P ^a,f   Guymer, Robyn ^g   Essex, Rohan W ^h   Morlet, Nigel ⁱ   Gillies, Mark C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Marsden Eye Specialists   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Retina Associates   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h CANBERRA HOSPITAL   (Australia)

ⁱ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Field of vision; Macula; Neovascularisation; Retina; Vision

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

AGE RELATED MACULAR DEGENERATION; ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; DRUG SUBSTITUTION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; RETINA; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; WET MACULAR DEGENERATION;

ANGIOGENESIS INHIBITORS; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MIDDLE AGED; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINA; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 85002498920     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2015-308090     Document Type: Article

References (25)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004;291:1900-1.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31
3. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44
4. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98
5. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-48
6. Holash J, Davis S, Papadopoulos N, et al. VEGF-trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-8
7. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171-85
8. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008;92:667-8
9. Krohne TU, Liu Z, Holz FG, et al. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol 2012;154:682-6.e2.
10. Keane PA, Liakopoulos S, Ongchin SC, et al. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49:3115-20.
11. Forooghian F, Cukras C, Meyerle CB, et al. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 2009;29:723-31.
12. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
13. Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 2008;115:2199-205.
14. Gasperini JL, Fawzi AA, Khondkaryan A, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 2012;96:14-20.
15. Gillies MC, Walton R, Liong J, et al. Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project. Retina 2014;34:188-95.
16. Cleveland WS, Grosse E, Shyu WM. Local regression models. Statistical Models in S. Wadsworth & Brooks/Cole, 1992.
17. Arcinue CA, Ma F, Barteselli G, et al. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J Ophthalmol 2015;159:426-36.e2.
18. Chang AA, Li H, Broadhead GK, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology 2014;121:188-92.
19. Gillies MC, Campain A, Barthelmes D, et al. Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study. Ophthalmology 2015;122:1837-45.
20. Kumar N, Marsiglia M, Mrejen S, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2013;33:1605-12.
21. Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120: 2292-9.
22. Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol 2013;156:29-35.e2.
23. Ho VY, Yeh S, Olsen TW, et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol 2013;156:23-8. e2.
24. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
25. Rubin DB. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med 2007;26:20-36.